US Stock Insider Trading | Pacific Biosciences disclosed three insider transactions on March 4th

K-LinePoet · 2026-03-29T15:30:18+00:00

On March 4, 2026, Pacific Biosciences disclosed that several executives engaged in insider trading on March 3, with HENRY CHRISTIAN O selling 12,500 shares at a price of $1.51. The company focuses on advanced sequencing solutions to promote the development of genomic research.

K-LinePoet

2026-03-29 15:30:18

Abstract generation in progress

On March 4, 2026, Pacific Biosciences (PACB) disclosed three transactions involving company insiders. Executive HENRY CHRISTIAN O sold 12,500 shares on March 3, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 4, 2026	Executive	Farmer Michele	March 3, 2026	Sell	2,979	1.51	4,510.21
March 4, 2026	Executive	Van Oene Mark	March 3, 2026	Sell	6,504	1.51	9,847.06
March 4, 2026	Executive	HENRY CHRISTIAN O	March 3, 2026	Sell	12,500	1.51	18,875.00
February 19, 2026	Executive	Van Oene Mark	February 17, 2026	Sell	129,800	1.58	204,458.00
February 19, 2026	Executive	Farmer Michele	February 17, 2026	Sell	35,200	1.58	55,536.00
February 19, 2026	Executive	Farmer Michele	February 18, 2026	Sell	15,000	1.63	24,450.00
February 19, 2026	Executive	HENRY CHRISTIAN O	February 17, 2026	Sell	331,800	1.58	522,564.00
February 19, 2026	Executive	HENRY CHRISTIAN O	February 18, 2026	Sell	140,900	1.63	229,847.00
February 19, 2026	Executive	Van Oene Mark	February 18, 2026	Sell	55,100	1.63	89,933.00
August 20, 2025	Executive	Van Oene Mark	August 18, 2025	Sell	26,800	1.31	35,108.00

【Company Information】

Pacific Biosciences of California, Inc. was founded in 2000 in Delaware. The company is a leading life sciences technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to enhance their understanding of genomes and ultimately address complex genetic issues. The company’s research and development products and technologies are based on two highly differentiated core technologies, focusing on accuracy, quality, and completeness, including the existing HiFi long-read sequencing technology and the emerging Sequencing by Binding short-read sequencing technology. The company’s products encompass a wide range of applications, including human genomics sequencing, plant and animal sciences, infectious diseases and microbiology, oncology, and other emerging applications.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.